AB 1320 adds Section 127698 to the Health and Safety Code to stop state agencies from awarding noncompetitive contracts for opioid antagonists to contractors that have entered into multistate settlement agreements tied to their role in the opioid epidemic. If a contract violates the ban, the bill renders that contract void and unenforceable and applies the rule retroactively to contracts entered into before January 1, 2026.
The bill targets procurement choices made under the California Affordable Drug Manufacturing Act of 2020 and is designed to prevent state purchases from effectively rewarding firms that settled multistate opioid litigation. For public health and procurement officials, this creates an immediate vendor-eligibility filter for naloxone and similar products and raises operational questions about vendor vetting, supply continuity, and contract management.
At a Glance
What It Does
The bill prohibits state agencies from awarding noncompetitive (sole-source or otherwise negotiated) contracts for opioid antagonists to any contractor that has entered into a multistate settlement agreement related to contributing to the opioid epidemic. It declares any contract that violates this prohibition void and unenforceable and applies that rule retroactively to contracts entered into before January 1, 2026.
Who It Affects
State procurement agencies operating under the California Affordable Drug Manufacturing Act, suppliers of naloxone and other FDA-approved opioid antagonists, and firms that previously entered multistate opioid settlement agreements. Indirectly, health care providers and public health programs that rely on state contracts for overdose-reversal drugs will be affected.
Why It Matters
The bill ties procurement eligibility to corporate conduct in opioid litigation, which could change which suppliers win state business and how agencies manage risk. It creates a new compliance step in procurement and a potential legal exposure for past contracts that were negotiated on a noncompetitive basis.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
AB 1320 inserts a single new section—127698—into California's Health and Safety Code. The section carves out a narrow but powerful prohibition: under the Affordable Drug Manufacturing Act framework, a state agency cannot award a contract on a noncompetitive basis for an "opioid antagonist" to any contractor that has signed a multistate settlement agreement for its role in contributing to the opioid epidemic.
The bill does not ban competitive awards; it focuses on noncompetitive instruments that bypass open competition.
The statute makes a violative contract void and unenforceable. That is a blunt remedial choice: the contract is not merely subject to cancellation or fines, it lacks enforceability from the outset.
The text expressly applies this remedy retroactively to any contract entered into before January 1, 2026, meaning existing sole-source or negotiated deals for naloxone or similar drugs can be invalidated if the contractor falls within the covered settlement class.The bill defines "opioid antagonist" by example—naloxone hydrochloride—and by function: any FDA-approved drug that negates opioid effects and is approved to treat opioid overdose. The procurement prohibition therefore captures naloxone formulation purchases and other FDA-approved antagonists used for overdose reversal.
Practically, procurement offices will need to build vendor-screening against the universe of multistate settlement signatories, adjust contract templates and award methods, and plan for continuity if a current supplier becomes ineligible or an existing contract is voided.What the bill does not do is specify an administrative process for determining whether a contractor "entered into a multistate settlement agreement" (for example, whether private settlements, criminal pleas, or certain partial settlements qualify), nor does it provide transitional procurement authority, emergency procurement exceptions, or replacement funding to secure alternative supplies. Those gaps create immediate implementation questions for CHHSA and other state agencies responsible for drug acquisition.
The Five Things You Need to Know
The bill adds Section 127698 to the Health and Safety Code and operates "notwithstanding Section 127692," tying the rule directly to procurement authorized under the Affordable Drug Manufacturing Act.
It forbids only noncompetitive awards (sole-source or negotiated contracts); it does not bar suppliers from winning contracts through competitive procurement.
A contract that violates the prohibition is declared void and unenforceable—there is no statutory backstop, damages formula, or cure period specified.
The prohibition applies retroactively to any contract entered into before January 1, 2026, exposing pre-existing noncompetitive contracts to invalidation.
The statute defines "opioid antagonist" to include naloxone hydrochloride and any FDA-approved drug that negates opioid effects and is approved to treat opioid overdose.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Ban on noncompetitive contracts with multistate-settlement contractors
Subsection (a) prohibits state agencies, under the Affordable Drug Manufacturing Act authority, from awarding contracts on a noncompetitive basis for opioid antagonists to any contractor that has entered into a multistate settlement agreement for contributing to the opioid epidemic. Operationally, this directs procurement officers to exclude certain vendors from sole-source or negotiated procurement methods; it leaves open competitive procurement but narrows the methods agencies may use when selecting a supplier.
Voidability of violating contracts
Subsection (b) states that any contract in violation of the prohibition is void and unenforceable. That language removes statutory support for enforcement, but it does not set out procedural guidance—such as notice, cure, or replacement procurement—so agencies and suppliers will face immediate legal uncertainty when an awarded contract runs into this barrier.
Retroactive application to pre‑2026 contracts
Subsection (c) applies the prohibition retroactively to contracts entered before January 1, 2026. Retroactivity means existing noncompetitive contracts for opioid antagonists could be invalidated if the contractor is a covered settlement signatory. That raises practical questions about supply continuity, liability for performance already rendered, and any downstream impacts on providers who depend on those supplies.
Definition of 'opioid antagonist'
Subsection (d) defines the covered products as naloxone hydrochloride or any FDA‑approved drug that negates opioid effects and is approved for treating opioid overdose. The definition is tied to FDA approvals and the clinical function of the drug, making it product‑specific but flexible enough to include future approved antagonists.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- State policymakers and advocacy groups seeking accountability: The provision prevents state funds from flowing on a noncompetitive basis to firms that settled multistate opioid litigation, aligning procurement choices with accountability goals.
- Competing suppliers that did not enter multistate settlements: Firms that avoided such settlements gain a relative advantage in noncompetitive award situations because certain competitors become ineligible for sole‑source contracts.
- Taxpayers and public purchasers concerned about moral hazard: The ban aims to reduce the appearance that state purchasing rewards firms linked to the opioid crisis, which can be politically and fiscally important for accountability-minded stakeholders.
Who Bears the Cost
- Suppliers that signed multistate opioid settlement agreements: Those firms lose eligibility for noncompetitive award paths under this chapter and may see curtailed state business where sole‑source deals were previously used.
- State procurement and health agencies (CHHSA and departments): Agencies must add vendor‑screening, legal review, and contingency planning to procurement operations, and may face supply interruptions if existing contracts are voided.
- Public health providers and harm‑reduction programs: If an essential supplier is excluded or a preexisting noncompetitive contract is voided, programs that rely on state procurement for naloxone could face short-term shortages or administrative delays.
Key Issues
The Core Tension
The bill balances two legitimate aims that pull in opposite directions: enforcing accountability by withholding preferential state procurement from firms tied to the opioid epidemic, and preserving reliable, rapid access to life‑saving overdose medications through stable procurement channels; the statute privileges the first aim without building institutional pathways to protect the second.
The bill's core enforcement tool—voiding contracts—creates immediate practical and legal friction. Retroactive voiding of preexisting contracts can interrupt supply chains for naloxone without providing a statutory replacement mechanism or emergency procurement exception.
Procurement officers will need to reconcile public‑health urgency (ensuring uninterrupted access to overdose reversal drugs) with the statutory ban, but the statute offers no prioritized path or funding to secure alternative suppliers.
The statute leaves several definitional and administrative questions unanswered. It does not define what qualifies as a "multistate settlement agreement" (does it include partial state settlements, civil-only agreements, or negotiated releases that are not publicly identified as "multistate"?), nor does it prescribe a verification process, notification duty, or appeal mechanism for vendors.
Those gaps invite litigation over the statute's reach and require agencies to develop due‑diligence protocols under time pressure. There is also a real risk of perverse outcomes: excluding key producers could reduce state bargaining power or cause short-term price increases if only a few competitive suppliers remain.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.